According to Correio da Manhã, Paula Freitas points to a co-payment of “between 30% and 40%” and “especially for the medications Wegovi and Mounjaro, whose active ingredients are semaglutide and tirzepatide”.

"Ozempic is very well known, but the 1 milligram dosage is too low for obesity and is intended for the treatment of diabetes," she added.

Earlier this week, the Minister of Health, Ana Paula Martins, revealed that Infarmed is analysing the co-payment for these medications following a recommendation from the World Health Organization (WHO) to expand the use of these medications and to make them universally and financially accessible.